165 related articles for article (PubMed ID: 35655778)
41. Diagnosis and management of Castleman disease.
Soumerai JD; Sohani AR; Abramson JS
Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
[TBL] [Abstract][Full Text] [Related]
42. Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospital.
González-García A; Patier de la Peña JL; García-Cosio M; Sarhane Y; Sánchez Díaz C; Barbolla Díaz I; López Rodríguez M; Moreno MÁ; Villarubia J; Manzano L
Leuk Lymphoma; 2019 Dec; 60(14):3442-3448. PubMed ID: 31305183
[TBL] [Abstract][Full Text] [Related]
43. The clinical spectrum of Castleman's disease.
Dispenzieri A; Armitage JO; Loe MJ; Geyer SM; Allred J; Camoriano JK; Menke DM; Weisenburger DD; Ristow K; Dogan A; Habermann TM
Am J Hematol; 2012 Nov; 87(11):997-1002. PubMed ID: 22791417
[TBL] [Abstract][Full Text] [Related]
44. Unicentric or Multicentric Castleman disease? A case report of a pelvic intraperitoneal mass in a middle aged woman.
Smedile A; Capuano F; Fraticelli S; Lucioni M; La Fianza A
J Radiol Case Rep; 2019 Mar; 13(3):28-36. PubMed ID: 31565175
[TBL] [Abstract][Full Text] [Related]
45. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
46. Castleman disease- demographics, associations, and outcomes: an analysis of adult 791 cases.
Patel R; Patel D; Onyechi A; Shaikh S; Patel M; Patel Z
Ann Hematol; 2024 Apr; 103(4):1255-1260. PubMed ID: 38040860
[TBL] [Abstract][Full Text] [Related]
47. Tentative diagnostic criteria and disease severity classification for Castleman disease: A report of the research group on Castleman disease in Japan.
Fujimoto S; Koga T; Kawakami A; Kawabata H; Okamoto S; Mizuki M; Yano S; Ide M; Uno K; Yagi K; Kojima T; Mizutani M; Tokumine Y; Nishimoto N; Fujiwara H; Nakatsuka SI; Shiozawa K; Iwaki N; Masaki Y; Yoshizaki K
Mod Rheumatol; 2018 Jan; 28(1):161-167. PubMed ID: 28880697
[TBL] [Abstract][Full Text] [Related]
48. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy.
Chronowski GM; Ha CS; Wilder RB; Cabanillas F; Manning J; Cox JD
Cancer; 2001 Aug; 92(3):670-6. PubMed ID: 11505414
[TBL] [Abstract][Full Text] [Related]
49. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.
Zhou QY
World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591
[TBL] [Abstract][Full Text] [Related]
50. [Castleman disease. Histopathological and immunohistochemical analysis of 39 cases].
Sevilla-Lizcano DB; Frias-Soria CL; Ortiz-Hidalgo C
Gac Med Mex; 2017; 153(5):550-558. PubMed ID: 29099112
[TBL] [Abstract][Full Text] [Related]
51. Use of a claims database to characterize and estimate the incidence rate for Castleman disease.
Munshi N; Mehra M; van de Velde H; Desai A; Potluri R; Vermeulen J
Leuk Lymphoma; 2015 May; 56(5):1252-60. PubMed ID: 25120049
[TBL] [Abstract][Full Text] [Related]
52. Clinical and experimental study of Castleman disease in children.
Zhang J; Li C; Lv L; Yang C; Kong XR; Zhu J; Zhang Y; Wang S
Pediatr Blood Cancer; 2015 Jan; 62(1):109-14. PubMed ID: 25213773
[TBL] [Abstract][Full Text] [Related]
53. [Clinical analysis of 30 cases of Castleman disease with different types of thoracic involvement].
Zhang XX; Jiang L; Wang CY; Gu YY; Li LG; Xia TT; Huang Y; Huang PK; Zhang QL
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):149-156. PubMed ID: 32135633
[No Abstract] [Full Text] [Related]
54. Treatment and Outcome of Castleman Disease: A Retrospective Report of 31 Patients.
Tang D; Guo Y; Tang Y; Wang H
Ther Clin Risk Manag; 2022; 18():499-509. PubMed ID: 35502435
[TBL] [Abstract][Full Text] [Related]
55. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation.
Abdallah NH; Habermann T; Buadi FK; Gertz MA; Lacy MQ; Rajkumar SV; Dingli D; Go RS; Hayman SR; Kumar SK; Kourelis T; Warsame R; Kapoor P; Muchtar E; Hwa YL; Fonder AL; Hobbs MA; Lin Y; Leung N; Binder M; Siddiqui MA; Kyle RA; Witzig TE; Dispenzieri A
Am J Hematol; 2022 Apr; 97(4):401-410. PubMed ID: 35015310
[TBL] [Abstract][Full Text] [Related]
56. Overview of Castleman disease.
Dispenzieri A; Fajgenbaum DC
Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
[TBL] [Abstract][Full Text] [Related]
57. Treatment of unicentric Castleman disease with neoadjuvant rituximab.
Bandera B; Ainsworth C; Shikle J; Rupard E; Roach M
Chest; 2010 Nov; 138(5):1239-41. PubMed ID: 21051400
[TBL] [Abstract][Full Text] [Related]
58. The heterogeneity of Castleman disease: report of five cases and review of the literature.
Maslovsky I; Uriev L; Lugassy G
Am J Med Sci; 2000 Oct; 320(4):292-5. PubMed ID: 11061358
[TBL] [Abstract][Full Text] [Related]
59. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
[TBL] [Abstract][Full Text] [Related]
60. Diagnosis and Management of Castleman Disease.
Abramson JS
J Natl Compr Canc Netw; 2019 Nov; 17(11.5):1417-1419. PubMed ID: 31766018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
